Actively Recruiting
Phase 1b Study of Eribulin with Irinotecan and Temozolomide to Treat Children and Young Adults With Relapsed or Refractory Solid Tumors
Led by M.D. Anderson Cancer Center · Updated on 2026-05-20
48
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best dose of eribulin when given together with irinotecan and temozolomide to treat children and young adults aged 1 to 25 years who have relapsed or refractory solid tumors. This phase Ib trial aims to find the maximum tolerated dose and recommended phase 2 dose of eribulin combined with fixed doses of irinotecan and temozolomide. The study also monitors safety, tolerance, and disease response including tumor activity and progression-free survival. Participants will receive treatment in one of several groups based on their tumor type, including Ewing sarcoma, rhabdomyosarcoma, other solid tumors, or dose finding levels. Eribulin and irinotecan are given by vein IV, while temozolomide is taken by mouth. The first phase involves dose escalation to determine the recommended dose combination, after which patients receive treatment at that dose in the expansion phase. During the study, participants will be closely monitored for side effects using standardized criteria and evaluated for tumor response and symptom relief. Assessments include physical exams, laboratory tests, and imaging to track disease status. The study will continue through completion with an average follow-up of about one year to observe safety and treatment outcomes in this population.
CONDITIONS
Brief Title
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Research Team
F
Fiorela Hernandez Tejada, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here